Pirinç Ö., Alan H., Gül M., Çetiner Y.
İnönü üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi, cilt.13, sa.2, ss.265-280, 2025 (Scopus)
Özet
This study investigated the effect of denosumab on new bone formation, both alone and in combination with different graft materials. To this end, four defects were created in the skulls of 20 New Zealand rabbits. One defect was left empty, while the other three were treated with autograft, xenograft, and calcium phosphate (BCP) grafts. The animals were divided into an experimental group (n=10), which received 10 mg/kg of denosumab subcutaneously once a month for 2 months, and a control group (n=10), which was administered the same dose of physiological saline. After 8 weeks, the animals were sacrificed, and their bone tissue samples were analyzed histomorphometrically. The percentage of bone volume (PBV) was calculated by dividing the area of mature bone tissue by the total tissue area. The PBV in empty defects treated with denosumab was significantly higher than in the control group (p < 0.05). Moreover, the combination of denosumab and autograft resulted in a significant increase in new bone formation (NBF) (p < 0.05), thus demonstrating the positive effect of denosumab on bone formation. However, further research with larger experimental groups would be needed to determine the practicality, dosage, and duration of this treatment before clinical application.